FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to therapeutic peptides originating from human HMGB1; it can be used in medicine for tissue regeneration. Modified peptides are obtained based on a human HMGB1 fragment, having activity relatively to migration of stromal and mesenchymal cells of bone marrow origin, in particular PDGFRα-positive cells, and increased stability in blood plasma compared to an unmodified human HMGB1 fragment 2-44.
EFFECT: obtaining peptides for tissue regeneration.
8 cl, 1 tbl, 6 ex, 3 dwg
Title | Year | Author | Number |
---|---|---|---|
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
Authors
Dates
2022-05-30—Published
2018-04-24—Filed